drugset / Trial / NCT04473664
A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Quizartinib is a novel oral Class III receptor tyrosine kinase (RTK) inhibitor exhibiting highly potent and selective but reversible inhibition of Feline McDonough sarcoma (FMS)-like tyrosine kinase 3 (FLT3). Quizartinib is currently being studied alone or in combination with other agents as a treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in adult and pediatric populations.
Timeline
- Start
- 2020-09-22
- Primary completion
- 2021-07-22
- Completion
- 2021-07-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quizartinib | Small molecule | 30 mg | Oral |